These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 11082979)
21. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. Nelson HD JAMA; 2004 Apr; 291(13):1610-20. PubMed ID: 15069049 [TBL] [Abstract][Full Text] [Related]
22. Ultra-low dose - new approaches in menopausal hormone therapy. Stute P; Becker HG; Bitzer J; Chatsiproios D; Luzuy F; von Wolff M; Wunder D; Birkhäuser M Climacteric; 2015 Apr; 18(2):182-6. PubMed ID: 25335192 [TBL] [Abstract][Full Text] [Related]
23. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Simon J; Klaiber E; Wiita B; Bowen A; Yang HM Menopause; 1999; 6(2):138-46. PubMed ID: 10374221 [TBL] [Abstract][Full Text] [Related]
24. 0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes. Gerlinger C; Gude K; Schmelter T; Schaefers M; Endrikat J Climacteric; 2015; 18(4):512-7. PubMed ID: 26000627 [TBL] [Abstract][Full Text] [Related]
26. Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens. Utian WH; Lederman SA; Williams BM; Vega RY; Koltun WD; Leonard TW Obstet Gynecol; 2004 Feb; 103(2):245-53. PubMed ID: 14754691 [TBL] [Abstract][Full Text] [Related]
27. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Reddy SY; Warner H; Guttuso T; Messing S; DiGrazio W; Thornburg L; Guzick DS Obstet Gynecol; 2006 Jul; 108(1):41-8. PubMed ID: 16816054 [TBL] [Abstract][Full Text] [Related]
28. A review of transdermal nonpatch estrogen therapy for the management of menopausal symptoms. Carroll N J Womens Health (Larchmt); 2010 Jan; 19(1):47-55. PubMed ID: 20088658 [TBL] [Abstract][Full Text] [Related]
29. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Stevenson JC; Durand G; Kahler E; Pertyński T Maturitas; 2010 Nov; 67(3):227-32. PubMed ID: 20688442 [TBL] [Abstract][Full Text] [Related]
30. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Carranza-Lira S; Gooch AL; Saldivar N; Osterwalder MS Int J Fertil Womens Med; 2007; 52(2-3):93-6. PubMed ID: 18320867 [TBL] [Abstract][Full Text] [Related]
31. Spray-on estrogen effective in relieving menopausal hot flashes. Mayo Clin Womens Healthsource; 2008 Dec; 12(12):3. PubMed ID: 18985020 [No Abstract] [Full Text] [Related]
32. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials. Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058 [TBL] [Abstract][Full Text] [Related]
33. Costs of hormonal and nonhormonal prescription medications for hot flashes. Williams-Frame A; Carpenter JS Womens Health (Lond); 2009 Sep; 5(5):497-502. PubMed ID: 19702449 [TBL] [Abstract][Full Text] [Related]
34. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss. Komm BS; Mirkin S; Jenkins SN Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044 [TBL] [Abstract][Full Text] [Related]